Research Articlehepatitis C

Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

See allHide authors and affiliations

Science Translational Medicine  04 Jan 2012:
Vol. 4, Issue 115, pp. 115ra1
DOI: 10.1126/scitranslmed.3003155

Abstract

Currently, no vaccine exists for hepatitis C virus (HCV), a major pathogen thought to infect 170 million people globally. Many studies suggest that host T cell responses are critical for spontaneous resolution of disease, and preclinical studies have indicated a requirement for T cells in protection against challenge. We aimed to elicit HCV-specific T cells with the potential for protection using a recombinant adenoviral vector strategy in a phase 1 study of healthy human volunteers. Two adenoviral vectors expressing NS proteins from HCV genotype 1B were constructed based on rare serotypes [human adenovirus 6 (Ad6) and chimpanzee adenovirus 3 (ChAd3)]. Both vectors primed T cell responses against HCV proteins; these T cell responses targeted multiple proteins and were capable of recognizing heterologous strains (genotypes 1A and 3A). HCV-specific T cells consisted of both CD4+ and CD8+ T cell subsets; secreted interleukin-2, interferon-γ, and tumor necrosis factor–α; and could be sustained for at least a year after boosting with the heterologous adenoviral vector. Studies using major histocompatibility complex peptide tetramers revealed long-lived central and effector memory pools that retained polyfunctionality and proliferative capacity. These data indicate that an adenoviral vector strategy can induce sustained T cell responses of a magnitude and quality associated with protective immunity and open the way for studies of prophylactic and therapeutic vaccines for HCV.

Introduction

Hepatitis C virus (HCV) is a major cause of liver disease globally. The virus is readily able to set up persistent infection in immunocompetent hosts, leading to chronic liver inflammation, cirrhosis, liver failure, and liver cancer (1). Current treatments, although improving rapidly, are costly, imperfect, and associated with major side effects. A vaccine to prevent chronic infection would be a major step forward.

HCV may be spontaneously controlled in a proportion of those infected. Many studies of the host genetics and immunology demonstrate an important role for T cells in protective immunity against HCV (25). Although there is no single correlate of immune protection, many studies have indicated that CD4+ and CD8+ T cell responses that are broadly directed (for example, target multiple viral antigens), functional [for example, produce interferon-γ (IFN-γ) and maintain proliferative capacity], and sustained over time are linked to virologic control (2, 3, 6). In chimpanzee models, depletion of either CD4+ or CD8+ T cells in vivo abrogates protective immunity induced by previous HCV exposure (4, 5). Although other mechanisms contribute to naturally induced host defense, including innate responses and neutralizing antibodies (NAbs) (7, 8), these data suggest that induction of robust T cell responses through vaccination could provide effective immune control of acute HCV infection.

This hypothesis has been tested in the chimpanzee challenge model by Folgori and colleagues using a target immunogen spanning the nonstructural genes NS3-NS5B from HCV genotype 1B, a region that contains many well-defined CD4+ and CD8+ epitopes, delivered in the form of recombinant, replication-deficient human adenovirus constructs (9). In the vaccinated animals, strong CD8+ and CD4+ T cell responses were induced, and upon challenge, the brisk anamnestic response was linked with viral control in four of five animals. Thus, vaccination protocols that induce broad, sustained, and functional T cell responses may protect against persistent infection by limiting early viral replication upon challenge.

To test whether such an approach could be successful in man, we used two adenoviral vectors based on rare serotypes to induce T cell responses against HCV in healthy volunteers. Virally vectored vaccines have been used in many approaches to protect against infection. Among these, adenoviral vectors have shown superior capacity to prime immune responses compared to approaches such as modified vaccinia Ankara (MVA) (10). Adenoviral vectors, however, suffer from the limitation that adenoviral infection in man is common and preexisting high-titer NAbs may interfere with the vaccine efficacy: The use of rare serotypes may overcome this limitation. We therefore used vectors based on Ad6 (adenovirus 6), a virus with a seroprevalence of about 22%, and ChAd3 (chimpanzee adenovirus 3), which is serologically distinct and has a seroprevalence of about 12% (11). We tested the safety and potency of such vaccines singly and in combination as a prime boost regimen.

Our data show good safety profiles of vaccination regimes associated with priming of CD8+ and CD4+ T cell responses by both vaccines, targeting multiple antigen regions and sustained up to 1 year. These responses mimic those associated with protection in natural infection. This approach shows promise for T cell–based vaccination against HCV.

Results

Safety

Overall, we found the administration of vaccine to be safe and well tolerated. Mild local and systemic side effects, comparable to those previously reported with other adenoviral vectors, were observed. These increased with dose but were short-lived and did not differ significantly between the two vectors or between priming and boosting (fig. S1). No serious adverse events occurred. The overall study design is described in table S1.

Ad6-NSmut– and ChAd3-NSmut–primed T cell responses in healthy volunteers

We first assessed the immunogenicity of the priming regimens using escalating doses of each vector in groups of four to five healthy donors. Each vaccine was administered twice at 0 and 4 weeks.

IFN-γ enzyme-linked immunospot (ELISpot) studies during dose escalation revealed responses detectable over the first 24 weeks in all groups, with three of four, four of four, and five of five responding in the Ad6-NSmut–primed groups and one of four, three of four, and five of five individuals showing responses after low-, medium-, and high-dose regimens using the comparable ChAd3-NSmut vector. Figure 1, A and B, shows the peak magnitude of these responses in the groups by individual volunteers. The peak response was seen at weeks 2 to 6 after prime, depending on the individual: In the high-dose groups, the peak responses were detectable at a median of >1000 IFN-γ spot-forming cells (SFCs) per 106 peripheral blood mononuclear cells (PBMCs) (Ad6-NSmut: median, 1202; range, 443 to 4263; ChAd3-NSmut: median, 1400; range, 642 to 3210).

Fig. 1

Magnitude of T cell responses primed after vaccination with Ad6-NSmut or ChAd3-NSmut. (A and B) Peak total IFN-γ ELISpot response ex vivo: ELISpot data from individuals vaccinated with (A) Ad6-NSmut (open symbols) (groups 1 to 3) (dose escalation, 5 × 108 to 2.5 × 1010 vp) and (B) ChAd3-NSmut (closed symbols) (groups 5 to 7) (dose escalation, 5 × 108 to 7.5 × 1010 vp). The responses shown are the total positive IFN-γ ELISpot response across all pools (see Materials and Methods) measured at peak response after prime (weeks 2 to 8). Bars, median. (C and D) Single versus double priming: the kinetics of the priming responses after (C) double prime (groups 3 and 7) and (D) single prime (groups 9 and 10) at high vaccine dose (2.5 × 1010 vp). Group medians and interquartile range (IQR) over time are shown. Open circles indicate Ad6-NSmut priming, and closed symbols indicate ChAd3-NSmut priming.

We also enrolled a further arm in which ChAd3-NSmut was administered at a higher dose [ChAd3-NSmut: 7.5 × 1010 viral particles (vp)]. However, this group did not show significantly enhanced priming than the previous highest dose (Fig. 1B), with some modest increases in local reactions, so overall an optimized tolerated dose of 2.5 × 1010 vp was achieved.

We also compared the two-dose priming regimen (dosing at weeks 0 and 4) with a single dose at 2.5 × 1010 vp (Fig. 1, C and D). The latter primed responses to similar levels as the two-dose priming regimen for both vectors [peak Ad6-NSmut: median, 1173; range, 245 to 3148; ChAd3-NSmut: median, 890; range, 300 to 2488 (SFCs) per 106 PBMCs between weeks 2 and 4]. The levels of response at later time points in the single-dose primed groups were lower than those in the double-primed groups (P = 0.02 at week 8), although kinetics were similar.

Overall, these data indicate consistent priming using these vectors, optimized at a dose of 2.5 × 1010 vp in both cases. For comparison, although there is no defined cutoff for a protective response, observational studies of the responses seen in individuals who acutely clear virus are typically in the region of hundreds of SFCs per million PBMCs (2, 3, 6, 9, 12), remaining detectable for many years (3).

Broad T cell responses from Ad6-NSmut and ChAd3-NSmut priming in healthy volunteers

The breadth of responses is reproducibly associated with control of virus in human correlative studies (2, 3, 12). Responses were assessed using peptides arranged into six pools corresponding to the viral gene products reproduced in the vaccine insert (pools F/G = NS3, pool H = NS4A/B, pool I = NS5A, pools L/M = NS5B). We assessed response breadth by analyzing how many pools elicited significant IFN-γ reactivity in the ELISpot. Across groups, response breadth increased with magnitude as vaccine dose was escalated (Fig. 2A); indeed, the two measures were correlated (r = 0.88, P < 0.0001; Fig. 2B).

Fig. 2

Breadth of T cell responses primed after vaccination with Ad6-NSmut or ChAd3-NSmut. (A) Breadth of primed response ex vivo: ELISpot data from individuals vaccinated with Ad6-NSmut (open symbols) (groups 1 to 3) (dose escalation, 5 × 108 to 2.5 × 1010 vp) and ChAd3-NSmut (closed symbols) (groups 5 to 7) (dose escalation, 5 × 108 to 2.5 × 1010 vp). The responses shown are the number of positive pools (see Materials and Methods) measured at peak magnitude after prime (weeks 2 to 8). Bars, median. (B) Correlation of breadth and magnitude: the number of positive pools [from (A)] compared with the magnitude of the ELISpot response (from Fig. 1, A and B) is plotted.

We analyzed the four groups (3, 7, 9, and 10) receiving the dose of 2.5 × 1010 vp of either vector up to week 4 and observed a median number of five pools recognized, with five donors recognizing all six pools.

Among these four comparable groups, we assessed the specificity of the primed response. Although all pools were targeted, pool G (NS3) was immunodominant (Fig. 3A) (P ≤ 0.0001). Individual volunteer data (Fig. 3B) showing the specificity at peak magnitude after priming with Ad6-NSmut and ChAd3-NSmut at 2.5 × 1010 vp are shown.

Fig. 3

Specificity of T cell responses primed after vaccination with Ad6-NSmut or ChAd3-NSmut. (A) Immunodominance of primed responses: Data are taken from the IFN-γ ELISpot responses from high-dose groups (3 and 9: Ad6-NSmut, 2.5 × 1010 vp; 7 and 10: ChAd3, 2.5 × 1010 vp) at peak magnitude after prime. The magnitude of the HCV-specific T cell response to individual peptide pools (F to M) and the corresponding NS protein below are shown. Bars, mean ± SEM. P = 0.0001. (B) Individual volunteer data showing targeted pools after priming with Ad6-NSmut (2.5 × 1010 vp, group 3) (upper panel) and ChAd3-NSmut (2.5 × 1010 vp, group 7) (lower panel).

Ad6-NSmut– and ChAd3-NSmut–primed functional CD4+ and CD8+ T cell responses in healthy volunteers

We next analyzed the functionality of the induced T cell responses and the contribution of CD4+ and CD8+ T cells. First, we analyzed CD4+ T cell proliferative responses against HCV recombinant proteins using 3H incorporation assays, comparable to those described in previous studies of natural protection (13, 14). We detected responses to multiple HCV proteins in most of the volunteers in the high-dose groups (fig. S2A). Reactivity was detectable against all antigens, although maximal against HCV NS3-derived antigens (fig. S2B; NS3 and NS3-derived helicase; P < 0.0002)

We also analyzed the functionality of the antiviral response induced by the vaccines using intracellular cytokine staining (ICS) for IFN-γ, TNFα (tumor necrosis factor–α), IL-2 (interleukin-2), and IL-17. Responses were elicited using two pools of peptides (F + G + H = NS3/4, I + L + M = NS5A/B) (Fig. 4). For both CD4+ and CD8+ T cell responses, we observed cytokine production, including IL-2, TNFα, and IFN-γ. For both vectors, the predominant population primed during the peak response was CD8+ T cells (Fig. 4 and fig. S3). To assess whether cells were making a polyfunctional response, we analyzed the production of single and multiple cytokines in the primed responses. We observed populations with joint IFN-γ/TNFα or IFN-γ/IL-2 production and co-production of all three cytokines; this was more balanced in the CD4+ T cell populations than in the CD8+ T cell populations, where IFN-γ single-producing or IFN-γ/TNFα double-producing populations were more dominant. Figure 4 shows data from high-dose groups (Ad6-NSmut and ChAd3-NSmut) and fig. S3 shows results from the dose titration. There were no significant differences between responses elicited by Ad6-NSmut compared to ChAd3-NSmut. We also analyzed IL-17A secretion because of recent data on function of liver-homing T cell populations (15), but minimal response was seen.

Fig. 4

Functionality of T cell responses primed after vaccination with Ad6-NSmut or ChAd3-NSmut. (A) Example FACS plots after ICS: Staining for IFN-γ/IL-2 and IFN-γ/TNF is shown for CD4+ and CD8+ T cell responses, respectively, after stimulation with F + G + H (NS3/4)–pooled peptides (see Materials and Methods) in three donors (037, group 7; 068, group 9; and 102, group 3; weeks 4 to 6). Plots are gated on live, CD3+, CD4+, or CD8+ T cell populations. (B and C) Group data for ICS after priming. SPICE analysis for combined ICS data (after stimulation with NS3/4 peptides) for CD8+ and CD4+ T cell responses after priming (2 to 4 weeks) from six volunteers each in high-dose groups (3, 7, 9, and 10; responses >0.05%). The pie charts (B) represent the proportion of cytokine-secreting cells that produce one, two, three, or four cytokines (IFN-γ, TNFα, IL-17, and/or IL-2). CD4+ and CD8+ T cells are shown on left and right plots, respectively. The graph in (C) shows individual cytokines produced alone and in combination as percent of total CD4+ and CD8+ T cells. Each dot (orange, CD8+; green, CD4+ T cells) represents responses in an individual. Black bars, mean response.

Cross-reactive T cell responses from Ad6-NSmut and ChAd3-NSmut priming

To assess whether the responses were cross-reactive against other HCV genotypes, we performed ELISpots using peptide pools representing consensus sequences from genotypes 1B (vaccine immunogen), 1A, and 3A. The latter is common in European intravenous drug–using populations and is highly divergent from the vaccine sequence. This approach revealed a close relationship between the response to the priming genotype 1B and the heterologous response (r = 0.89, P < 0.0001, genotype 1B compared with genotype 1A, and r = 0.80, P < 0.0001, genotype 1B compared with genotype 3A; Fig. 5). Overall, the response to genotype 1A was about half that of the response to genotype 1B, and that of genotype 3A was about a fifth, still significantly above the response thresholds set using negative controls.

Fig. 5

Cross-reactivity of T cell responses induced after vaccination with Ad6-NSmut or ChAd3-NSmut. (A) Cross-reactivity measured by IFN-γ ELISpot response ex vivo against genotype 1B with genotype 1A and 3A peptide pools (F, G, H, I, L, and M) in volunteers from group 11 (7.5 × 1010 vp ChAd3-NSmut) tested at week 4. (B) Correlation of IFN-γ ELISpot response ex vivo against genotype 1B with genotype 1A and 3A peptide pools: ELISpot data from individuals in group 11 (7.5 × 1010 vp ChAd3-NSmut) tested at week 4. Each symbol represents a single pool response in a single volunteer.

Ad6-NSmut and ChAd3-NSmut as heterologous boosting vectors

We next assessed the ability of the adenoviral vectors to boost in a heterologous manner—groups primed with ChAd3-NSmut vector were boosted with Ad6-NSmut vector (all at 2.5 × 1010 vp) and vice versa. Figure 6A shows the boosting from the two high-dose double-priming groups (groups 3 and 7). This figure demonstrates two features: First, there was some boosting of T cell frequencies seen compared to before boost (week 24), although the overall magnitude did not exceed that seen at priming. Second, the group primed with ChAd3-NSmut vector boosted better than the group primed with Ad6-NSmut: This was associated with a slightly higher number of pre-boost T cells in the former group. Similar observations were made in the single-primed groups (9 and 10; Fig. 6B). Figure S4 shows boosting data from the low and medium prime dose groups. Across all dose-escalation groups, a correlation was seen between the number of primed T cells and the number of boosted T cells (r = 0.7, P < 0.001; fig. S5).

Fig. 6

Boosting of T cell responses primed after vaccination with Ad6-NSmut or ChAd3-NSmut. (A and B) Boosting of primed responses: (A) Group data from IFN-γ ELISpot responses in high-dose double-prime groups (3: Ad6-NSmut, 2.5 × 1010 vp; 7: ChAd3-NSmut, 2.5 × 1010 vp) over time. The responses shown are the total positive IFN-γ ELISpot response across all pools (see Materials and Methods) presented as group medians and IQR. Open symbols indicate Ad6-NSmut priming (ChAd3-NSmut boost), and closed symbols indicate ChAd3-NSmut priming (Ad6-NSmut boost). (B) Similar data for groups 9 and 10 (single-prime groups). (C to F) NAb titers: Homologous (against priming vector) (C and D) and heterologous (against boosting vector) (E and F) NAb titers are presented as group medians and IQR. Open symbols indicate Ad6-NSmut priming (ChAd3-NSmut boost), and closed symbols indicate ChAd3-NSmut priming (Ad6-NSmut boost). (C and E) Double-primed groups 3 and 7. (D and F) Single-primed groups 9 and 10. (G and H) Adenovirus-specific responses after priming and boosting: group data from IFN-γ ELISpot responses in high-dose groups [double-prime (G) and single-prime (H) groups] over time. The responses shown are the total positive IFN-γ ELISpot response across Ad5 hexon peptides (see Materials and Methods) presented as group medians and IQR. Open symbols indicate Ad6-NSmut priming (ChAd3-NSmut boost), and closed symbols indicate ChAd3-NSmut priming (Ad6-NSmut boost).

These data raised the possibility that preexisting anti-vector antibodies may limit boosting of both HCV- and adenovirus-specific T cells. We evaluated this by measuring NAb titers against Ad6-NSmut and ChAd3-NSmut. In both cases, we found substantial levels of NAbs (titer >200) to both the homologous (Fig. 6, C and D) and, more importantly, the heterologous vector (Fig. 6, E and F), although this did not differ substantially between the groups. These data support the idea that NAbs against the boosting vector may play some role in limiting the overall boosting effect: The differential impact on the order of the regimens is not fully elucidated but may potentially reflect the different susceptibility of the adenoviral vectors to neutralization in vivo.

We also assessed the adenovirus-specific IFN-γ ELISpot responses in these groups using peptides representing the major adenoviral capsid hexon protein. Adenovirus-specific T cell responses were present at baseline and increased substantially after vaccination. Adenovirus-specific T cell responses did not associate with reduction in primed or boosted HCV-specific responses; indeed, there was a positive correlation between the boosting of adenovirus- and HCV-specific responses (Fig. 6, G and H).

Overall, we conclude that the boosting of responses after heterologous adenovirus/adenovirus vaccination is possible and correlates with the level of T cell priming. However, it may be blunted by anti-vector immunity, likely mediated by cross-reactive NAbs, at least up to 24 weeks after priming.

Tracking peptide-specific T cell responses

The analysis of peptide-specific responses was initiated by repeat testing of the PBMCs by ELISpot using smaller pools of peptides (“minipools”) (table S2). In HLA-A2+ (human leukocyte antigen–A2+) donors, the dominant minipool was found to contain a previously described immunodominant peptide (NS3 A2 1406-15 KLSGLGINAV), and in HLA-A1+ donors, a second pool contained a similarly immunodominant response (NS3 A1 ATDALMTGY).

To track responses to these peptides, we constructed fluorescent HLA-peptide multimers and analyzed the frequency, phenotype, and function of peptide-specific populations by flow cytometry. These data are summarized in Fig. 7, which shows representative fluorescence-activated cell sorting (FACS) plots of the NS3 A2 1406 response detected by multimer staining (Fig. 7A). Responses of up to 7% of the total CD8+ T cell response were readily detectable and persisted over a year (6 months after boost; Fig. 7B).

Fig. 7

Characterization of epitope-specific T cell responses induced after vaccination with Ad6-NSmut or ChAd3-NSmut. (A) Staining with tetramer A2-HCV-1406 KLSGLGINAV in a representative volunteer (volunteer 60, group 10) over the study time course. Gating is on live CD3+ (see Materials and Methods). Percent pentamer+/CD8+ T cells are shown. (B) Ex vivo tetramer+ CD8+ T cell responses over time in six volunteers who had an ELISpot response to pool Gb that contains the A2 1406 peptide (table S2; volunteers 32, 38, 105, 60, 64, and 68). Each received high-dose (2.5 × 1010 vp) ChAd3-NSmut or Ad6-NSmut. (C to F) Activation (C and D) and memory differentiation status (E and F) of pentamer+ cells (gated on CD8+ T cells). FACS plots (C and E) show a representative volunteer (060, group 10) at weeks 4 and 36 after ChAd3-NSmut prime (week 0) and Ad6-NSmut boost (week 8) (both 2.5 × 1010 vp). Percent given is the proportion of tetramer+ cells expressing the phenotypic y legend characteristic. The graphs (D and F) show percent pentamer+ cells (HLA-A2–HCV-1406 KLSGLGINAV and HLA-A1–HCV-1435 ATDALMTY) in nine individuals (HLA-A2: 032, 038, 060, 064, 068, and 105; HLA-A1: 19, 37, 66, and 68) expressing the phenotypic markers given in the x axis 4 weeks after single prime (red circles) or 4 weeks after second prime (black circles) and at the end of the study (week 52 for double-prime groups and week 36 for single-prime groups) (squares; red in the single-prime group and black in the double-prime group) after ChAd3-NSmut prime (week 0) and Ad6-NSmut boost (week 8) (both 2.5 × 1010 vp). Gates were set with the tetramer cell population as a reference.

Activation (CD38/HLA-DR) was only noted at the very earliest time points after the first priming vaccine and remained low thereafter (Fig. 7, C and D, and fig. S6B). The cells also expressed PD-1, a molecule that has been associated with both activation and exhaustion in persistent virus infection (16), although the PD-1 levels declined over time in a manner analogous to that seen in acute resolving HCV infection (17) (Fig. 7, C and D) and this was not associated with any clear dysfunction.

The responses had a mixed effector/central memory phenotype, which was sustained over time (Fig. 7, E and F); CD127, a molecule associated with long-term stable memory, was present on a proportion of the cells, with a significant increase over time (P < 0.05). The cells included CD45RACCR7+, CD45RACCR7, CD45RA+CCR7, and CD45RA+CCR7+ subsets, thus encompassing both effector and central memory populations (fig. S7). A stable proportion of the cells also expressed CD161 (15 to 20%); this molecule has also been observed as enriched on HCV-specific CD8+ T cells and its expression is linked to liver-homing populations (15). The cells appeared to contain cytolytic effector molecules, with high levels of granzymes A (GzA) and B (GzB), and variable levels of perforin (fig. S8).

Further analysis, using single-peptide stimulations in ICS assays, showed that CD8+ T cell populations maintained strong effector function, with secretion of IFN-γ, TNFα, and MIP1β, together with degranulation (CD107a). Some IL-2 secretion was noted (fig. S8). Polyfunctionality was assessed as previously and was maintained at high levels (fig. S9). They also showed maintained proliferative capacity, being able to expand in response to boost vaccination in vivo (fig. S6) as well as to peptide in vitro (fig. S10).

These analyses confirm epitope-specific memory populations maintained at high frequencies with a range of relevant antiviral effector functions.

Discussion

We report the first trial of a T cell–based preventive vaccine for HCV. The approach taken was to test two vectors based on replication-defective adenoviruses of rare serotypes. These were well tolerated, with a good safety profile. They were also highly immunogenic, with induction of CD4+ and CD8+ T cell responses targeting a wide range of antigens.

There were a number of important questions relating to a prophylactic vaccine. First, the responses need to be of sufficient magnitude to provide potential protection against persistent HCV infection. Our vectors were potent at priming responses, which often exceeded 1000 SFCs per million PBMCs, and responses were readily detected at 1 year by ELISpot. Multimer staining revealed readily detectable and functional responses at 1 year, indicative of a long-term memory population.

Second, the issue of response breadth is very important for HCV. Responses found in chronic infection are typically both low in magnitude and narrowly focused on a limited number of antigens or epitopes facilitating viral escape. We observed an increase in the breadth of the response linked to increasing size of the response. Because of the diversity of viral strains even within a single genotype or subtype, such breadth improves the chances of peptide recognition of the incoming strain, as well as limiting further escape in vivo.

The third important feature is the generation of both CD4+ and CD8+ T cell responses. It is known that strong CD4+ T cell responses are required for induction and maintenance of functional CD8+ T cell memory, and in HCV, it is clear that CD4+ T cell responses play a central role in host defense (4). We observed CD4+ T cell responses by intracellular staining, although, as expected, these were at lower frequencies than the corresponding CD8+ T cell responses. We also analyzed proliferation, using recombinant protein antigens, an assay that is a correlate of protective immunity (13). We observed strong and sustained CD4+ T cell responses targeting multiple antigens and comparable to those induced by natural infection and resolution.

Fourth, we assessed whether primed responses could target heterologous strains. The data here indicate that cross-strain recognition is possible, although of lower magnitude. To what extent a decrease in the T cell frequency would be associated with a decline in protection against challenge is not known. It is known that in natural infection, the immune selection pressure against genotypes 1 and 3 is almost completely distinct, suggesting that there may be many epitopes that are not shared and alternative vaccine approaches may be required (18).

In terms of functionality of CD8+ T cells, we observed strong secretion of IFN-γ and TNFα and sustained, although less dominant, secretion of IL-2, which is associated with “polyfunctional” populations linked to long-term host defense (19). The assays using peptide-specific analysis showed similar features of polyfunctionality, including degranulation (CD107a) and secretion of MIP1β, although direct cytotoxicity against infected hepatocytes is yet to be demonstrated. Similar cytokine secretion was demonstrated for CD4+ T cell populations.

The analysis of phenotype using class I tetramers showed a distinct phenotype. Responses showed markers of activation (CD38 and HLA-DR) at the earliest time points, and increasing levels of CD127 over time, consistent with emergence of at least a fraction of the cells as a long-term memory population (20). Although we saw increasing levels of CCR7, associated with “central” memory, there was a mixture over time of central and “effector” memory pools observed including CD45RA+ (both CCR7+ and CCR7-TEMRA) cells. The overall functional significance of this balance is not known. In HIV, we have observed an association between TEMRA frequencies and protection in acute HIV infection (21), and recent data in models of protection against simian immunodeficiency virus (SIV) suggest that induction of long-lived effector memory pools by cytomegalovirus (CMV) vectors can show a very high degree of protection (22). The peptide-specific cells demonstrated proliferative capacity both in vivo and in vitro, analogous to cells of a similar phenotype primed after yellow fever vaccination (23).

In the face of priming of such strong and functional responses, even greater boosting might have been expected, but this effect was relatively modest. The limitations on the post-boosting peak were not fully defined, but NAbs raised against the heterologous vector may limit host exposure to antigen. This was not the case seen in preclinical models (11), but in experimental animals, there is not extensive previous exposure to diverse adenoviral serotypes as in the volunteers. Heterologous NAbs were raised by both vectors despite low preexisting levels of antibody (a result of the screening procedure). The blunting of the ChAd3-NSmut boost (after Ad6-NSmut priming) was more marked in this trial than of the Ad6-NSmut boost, and because ChAd3-NSmut appears to be an excellent priming vector, this seems the appropriate priming choice for future studies. A single priming regimen may be sufficient, especially if a substantial boost can be obtained with different vectors.

Adenovirus/adenovirus prime boost regimes may give more marked boosts using alternative vector combinations. First, anti-vector T cells, which may be highly cross-reactive, did not seem to interfere with priming or boosting. Second, the adenoviral vectors used in this study belong to the same genetic subgroup (11), where serologic cross-reactivity may remain more of a problem; the use of adenovirus vectors from different genetic subgroups may provide a solution to this problem. As an alternative, a completely different boosting vector can be used and a trial to combine ChAd3-NSmut priming with the same insert in a MVA construct is now under way (EudraCT 2009-018260-10).

The future development of a prophylactic vaccine will hinge on identifying not only the optimal priming/boosting regimen but also a suitable high-risk cohort where such a strategy can be assessed in phase II clinical trials. Such cohorts have been identified in the United States, Canada, Australia, and the UK (24). In the United States, the predominant genotype in such groups is 1, and this will provide a crucial test of the success of this approach.

This vaccine may also be relevant to therapeutic strategies, potentially combined with other antiviral strategies. To what extent priming or boosting can be achieved in chronic HCV infection is now being assessed in an ongoing clinical study (EudraCT 2008-006127-32). Other therapeutic approaches using adjuvanted peptides (IC41) (25) and MVA-NS3/4A/5B vector (TG040) (26) have induced T cell responses in the order of 100 to 500 SFCs per million cells, associated with transient declines in viral load.

The ability to produce a vaccine is hampered by the huge diversity of HCV and its capacity to escape and to down-regulate T cell immunity. However, a substantial fraction of those infected are able to control the virus spontaneously, a feature that makes this effort distinct from HIV vaccines. What such a vaccine should optimally achieve is to accelerate the generation of immunity (which may include NAbs) after exposure and to enhance the chances of clearance (8). Overall, this work has shown that it is possible to generate very strong, broad, long-lasting, and functional T cell responses against HCV in healthy donors using an adenovirus-based approach. The next critical step will be to test whether these populations can be protective in vivo, such as in a setting where HCV exposure is common, and therefore whether this or related strategies can provide an effective vaccine against HCV.

Materials and Methods

Vaccination protocols

The Ad6 and ChAd3 vectors encoding the NS3-5B region of genotype 1B (Ad6-NSmut, based on sequence accession number M58335) have been described previously (9, 27). The vaccine study was registered as clinical trial EudraCT 2007-004259-12 and with the http://www.ClinicalTrials.gov database (ID: NCT01070407). All volunteers gave written informed consent before participation, and the studies were conducted according to the principles of the Declaration of Helsinki and in accordance with Good Clinical Practice. Volunteers were recruited at sites in Oxford and Birmingham, UK. Those with preexisting neutralizing titers against Ad6-NSmut or ChAd3-NSmut >200 were excluded. Vaccines were administered intramuscularly, and the volunteer group protocols are described in table S1.

Peptides and antigens

A set of 494 peptides, 15 amino acids in length, overlapping by 11 amino acids and spanning the open reading frame from NS3-NS5B (1985) of HCV genotype 1B strain BK, were obtained from BEI Resources. Peptides were initially dissolved in dimethyl sulfoxide (DMSO) and arranged into six pools (mean, 82; range, 73 to 112 peptides per pool) as indicated in fig. S11. Pools were used at a final concentration of 3 or 1 μg/ml (each single peptide) in ELISpot and intracellular staining, respectively. For cross-reactivity experiments, similar peptide pools derived from HCV genotype 1A (H77 strain) and genotype 3A (GenBank accession D28917) were also obtained and prepared identically. PepTivator-AdV5 Hexon pool (Miltenyi Biotec) was used at a final concentration of 1 μg/ml.

ELISpot assays

Ex vivo IFN-γ ELISpot assays were performed according to the manufacturer’s instructions (Mabtech) on freshly isolated PBMCs plated in triplicate at 2 × 105 PBMCs per well. To determine robust cutoffs, we screened 74 healthy HCV seronegative volunteers and established mean and SD of responses to HCV genotype 1B pools (fig. S12). For a positive response, the mean of antigen wells minus background was determined (i) to be greater than 48 SFCs/106 PBMCs (mean + 3 SD) and (ii) to exceed three times the background. Background wells (medium only, cells + DMSO) were typically zero to four spots. Internal positive controls included concanavalin A, FEC (mixed HLA class I–restricted peptides from flu, Epstein-Barr virus, and CMV), and CMV lysate. Total NS response was calculated by summing responses to all positive pools.

Proliferation assays

Ex vivo proliferation assays were performed on freshly isolated PBMCs plated in triplicate at 2 × 105 PBMCs per well with conventional [3H]thymidine incorporation methods and antigens (1 μg/ml) as indicated in fig. S11 (Mikrogen). Data are displayed as SI (stimulation index; fold change above background). A positive response is defined as SI ≥ 3.

Ad6-NSmut and ChAd3-NSmut NAb assays

Briefly, 3.5 × 104 human embryonic kidney (HEK) 293 cells per well were seeded in a 96-well plate for 2 days. Each SEAP-expressing adenoviral vector (28), incubated for 1 hour at 37°C alone or with serial dilutions of serum from trial volunteers, was then added to the 95 to 100% confluent HEK293 cells, incubated for 1 hour, and washed. SEAP expression was measured 24 hours later with the chemiluminescent substrate (CSPD), from the Phospha-Light kit (Tropix) without heat inactivation. Light emission (relative light units) was monitored 45 min after the addition of the CSPD substrate with the Envision 2102 Multi-label reader (Perkin Elmer).

Intracellular cytokine stains

Thawed PBMCs were stimulated with peptides in pool combinations (F + G + H = NS3/4, I + L + M = NS5A/B) or unstimulated (controlled for DMSO) or phorbol 12-myristate 13-acetate (PMA)/ionomycin (50 and 500 ng/ml, respectively). After overnight stimulation (brefeldin A was added after 1 hour at 10 μg/ml), cells were permeabilized (BD Perm) and stained with the following antibodies: CD3-PO, CD4–Qdot 605, CD8–PerCP (peridinin chlorophyll protein)–Cy5.5, IFN-γ–Alexa Fluor 700, IL-2–APC (allophycocyanin), TNFα–PE (phycoerythrin)–Cy7, and IL-17–PE. Flow cytometry was performed with a BD LSRII and analysis by FlowJo (TreeStar). Analysis of polyfunctionality was performed with SPICE (29).

Tetramer staining, short-term cell lines, and flow cytometry

For tetramer staining, PE-labeled pentamers loaded with HCV NS3 1406 (KLSALGINAV; HLA-A*0201) and HCV NS3 (ATDALMTGY, HLA-A*0101) were obtained from ProImmune. The cells were costained with combinations of the following antibodies: CD3-PO, CD8-PB, CCR7–PE-Cy7, CD45RA-FITC (fluorescein isothiocyanate), CD127-APC, CD38–PerCP-Cy5.5, HLA-DR–Alexa Fluor 700, perforin-FITC, GzB–Alexa Fluor 700, GzA–PerCP-Cy5.5, CD161-APC, and PD-1–PE-Cy7. Short-term cell lines were generated with peptide (10 μg/ml) and IL-2 (100 U/ml) on days 4 and 7, and cells were harvested on day 10 or 11.

For analysis of peptide-specific function, PBMCs were stimulated with the respective peptide at 1 μg/ml or control DMSO or PMA/ionomycin in the presence of anti-CD107a PE-Cy5. ICS was then performed as described above but stained with the following antibodies: CD3-PO, CD4–Qdot 605, CD8-PB, IFN-γ–Alexa Fluor 700, IL-2–APC, TNFα–PE-Cy7, and MIP1β-PE. Flow cytometry and analysis were performed as above.

Statistical analysis

Nonparametric tests were used, throughout, paired for within-individual comparisons (Wilcoxon) and unpaired for group comparisons (Mann-Whitney). For correlations, a nonparametric test was used (Spearman). For multiple comparisons, a one-way analysis of variance (ANOVA) with Bonferroni’s correction was used. Prism (v4.0 for Mac) was used throughout.

Supplementary Material

www.sciencetranslationalmedicine.org/cgi/content/full/4/115/115ra1/DC1

Fig. S1. Safety data after vaccination.

Fig. S2. Proliferative capacity of T cell responses after priming vaccination.

Fig. S3. Cytokine production with escalating vaccine dose.

Fig. S4. Kinetics of T cell responses over time with low/medium-dose vaccine.

Fig. S5. Correlation of T cell response post-boost with pre-boost and peak post-prime magnitude.

Fig. S6. In vivo proliferation of HCV-specific T cells.

Fig. S7. T cell maturation and differentiation status of pentamer+ HCV-specific T cells.

Fig. S8. T cell functional characteristics by ICS after peptide stimulation and by pentamer analysis.

Fig. S9. Polyfunctionality after peptide stimulation using SPICE analysis.

Fig. S10. In vitro proliferation of HCV-specific T cells at final study time point.

Fig. S11. HCV antigens in relation to the HCV viral genome.

Fig. S12. Defining ELISpot cutoff for positivity in healthy volunteers.

Table S1. Study design.

Table S2. Linkage of minipool specificity to HLA type.

Footnotes

  • * These authors contributed equally to this work.

References and Notes

  1. Acknowledgments: We thank the staff of the Centre for Clinical Vaccinology and Tropical Medicine and the Clinical Biomanufacturing Facility, Oxford, especially E. Berrie, A. Lawrie, K. Gantlett, and I. Poulton. We thank BEI for peptides. Funding: European Union (Framework VI; HEPACIVAC); Medical Research Council (UK); Wellcome Trust; Oxford NIHR Biomedical Research Centre; James Martin School for 21st Century, Oxford; Wellcome Trust Clinical Research Facility, Birmingham; National Institute for Health and Research Liver Biomedical Research Unit, Birmingham; and NIH grant 1U19AI082630-01. Author contributions: E.B., A.F., S. Capone, S. Colloca, G.O., D.A., A. Hill, A.N., and R.C. designed the study/protocols; E.B., S. Capone, L. Swadling, S.A., A.K., A. Harrison, J.M., R.H., K.S., R.T., A.B., R.A., V.A., M.N., C.W., G.O., F.G., M.L.E., L. Siani, and Y.O. performed the research and analysis; E.B., A.F., S. Capone, and P.K. wrote the manuscript; C.T. was the project manager; P.K. was the principal investigator. Competing interests: S. Colloca, A.F., R.C., and A.N. are named inventors on patent applications covering HCV-vectored vaccines and chimpanzee adenovirus vectors [WO 2006133911 (A3) hepatitis C virus nucleic acid vaccine, WO 2005071093 (A3) chimpanzee adenovirus vaccine carriers, WO 03031588 (A2) hepatitis C virus vaccine]. P.K. has acted as a consultant to Tibotec and Pfizer on antiviral therapy. Authors from Okairos are employees of and/or shareholders in Okairos. The other authors declare that they have no competing interests.
View Abstract

Navigate This Article